Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis

Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis

Abstract Introduction Lymphocyte depletion via anti-CD52 monoclonal antibody (mAb) therapy is an effective treatment strategy for relapsing–remitting multiple sclerosis (MS) but is associated with infusion/injection-associated reactions (IARs) and autoimmune-related adverse events (AEs). Gatralimab...

Full description

Saved in:
Bibliographic Details
Main Authors: Fredrik N. Albach, Christian Geier, Christian Keicher, Maximilian G. Posch, Stephan J. Schreiber, Gerald Grütz, Levent Akyüz, Xiaodong Luo, Annaig Le-Halpere, Philippe Truffinet, Frank Wagner
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-09-01
Series:Neurology and Therapy
Subjects:
Clinical trial
Disease-modifying therapies
Multiple sclerosis
Progressive
Treatment response
Online Access:https://doi.org/10.1007/s40120-024-00659-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40120-024-00659-w

Similar Items